<DOC>
	<DOC>NCT00721201</DOC>
	<brief_summary>The purpose of this study is to assess the effects of reducing the activity of endogenous glucocorticoid in patients with low-grade cortisol excess</brief_summary>
	<brief_title>Glucocorticoid Receptor Antagonism in Subclinical Cushings</brief_title>
	<detailed_description />
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Patients will be eligible for inclusion if: they are males and over 18, lack clinical features classically associated with Cushing's syndrome; have evidence of excess circulating cortisol Evidence of local or systemic malignancy; overt Cushing's syndrome; severe uncontrolled diabetes mellitus or hypertension; pregnancy; clinically significantly impaired cardiovascular function (e.g. stage IV cardiac failure); severe liver disease (liver enzymes â‰¥ 3 x the institutional upper limit of normal range); significantly impaired renal function (eGFR &lt;30/min); uncontrolled severe active infection; treatment with approved or experimental steroidogenesis inhibitors, adrenolytic agents, within four weeks of admission; In women, known endometrial cancer, history of endometrial hyperplasia or vaginal bleeding of unknown cause; requirement for inhaled or systemic glucocorticoids for existing disease; impaired mental capacity or markedly abnormal psychiatric evaluation that precludes informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>subclinical Cushing's</keyword>
</DOC>